CanSino Biologics Inc. (OTCMKTS:CASBF – Get Free Report) saw a significant decrease in short interest in the month of September. As of September 15th, there was short interest totaling 83,640 shares, a decrease of 82.8% from the August 31st total of 485,040 shares. Based on an average trading volume of 7 shares, the short-interest ratio is presently 11,948.6 days.
CanSino Biologics Price Performance
Shares of OTCMKTS:CASBF opened at C$2.95 on Friday. The stock’s 50-day moving average is C$3.61 and its 200-day moving average is C$3.52. CanSino Biologics has a 52-week low of C$2.60 and a 52-week high of C$6.99.
CanSino Biologics Company Profile
CanSino Biologics Inc is a China-based biopharmaceutical company focused on the research, development and commercialization of vaccine products. Headquartered in Tianjin, the company leverages an adenovirus vector platform to develop single-dose and recombinant vaccines targeting a range of infectious diseases. CanSino’s pipeline includes its authorized COVID-19 vaccine, Convidecia (Ad5-nCoV), as well as candidates for Ebola, influenza and other pathogens.
Since its founding in 2009, CanSino has built end-to-end capabilities spanning antigen discovery, process development and large-scale manufacturing.
Further Reading
- Five stocks we like better than CanSino Biologics
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for CanSino Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CanSino Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
